Published in J Clin Invest on July 01, 1995
Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol (2006) 1.83
Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia. J Vasc Surg (2008) 1.47
Sequential activation of the reactive oxygen species/angiotensinogen/renin-angiotensin system axis in renal injury of type 2 diabetic rats. Clin Exp Pharmacol Physiol (2008) 1.34
Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int J Biol Sci (2006) 1.27
Nox4 oxidase overexpression specifically decreases endogenous Nox4 mRNA and inhibits angiotensin II-induced adventitial myofibroblast migration. Hypertension (2008) 1.26
Different effects of angiotensin II and angiotensin-(1-7) on vascular smooth muscle cell proliferation and migration. PLoS One (2010) 1.18
Hepatocyte growth factor regulates human trophoblast motility and invasion: a role for nitric oxide. Br J Pharmacol (1999) 1.17
Crucial role of Rho-nuclear factor-kappaB axis in angiotensin II-induced renal injury. Am J Physiol Renal Physiol (2007) 1.16
Heightened efficacy of nitric oxide-based therapies in type II diabetes mellitus and metabolic syndrome. Am J Physiol Heart Circ Physiol (2008) 1.13
Integrin-associated protein stimulates alpha2beta1-dependent chemotaxis via Gi-mediated inhibition of adenylate cyclase and extracellular-regulated kinases. J Cell Biol (1999) 1.10
Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes. Am J Physiol Heart Circ Physiol (2010) 0.95
Angiotensin II, atherosclerosis, and aortic aneurysms. J Clin Invest (2000) 0.93
Endothelial nitric oxide synthase inhibits G12/13 and rho-kinase activated by the angiotensin II type-1 receptor: implication in vascular migration. Arterioscler Thromb Vasc Biol (2008) 0.93
Association of endothelial constitutive nitric oxide synthase gene polymorphism with acute coronary syndrome in Koreans. Heart (2004) 0.89
cGMP-dependent protein kinase Iβ regulates breast cancer cell migration and invasion via interaction with the actin/myosin-associated protein caldesmon. J Cell Sci (2013) 0.88
Nitric oxide function in atherosclerosis. Mediators Inflamm (1997) 0.87
Increased expression and co-localization of ACE, angiotensin II AT(1) receptors and inducible nitric oxide synthase in atherosclerotic human coronary arteries. Int J Physiol Pathophysiol Pharmacol (2010) 0.84
A Novel Systems-Biology Algorithm for the Analysis of Coordinated Protein Responses Using Quantitative Proteomics. Mol Cell Proteomics (2016) 0.83
Rho-kinase/nuclear factor-κβ/angiotensinogen axis in angiotensin II-induced renal injury. Hypertens Res (2011) 0.82
Alzheimer's disease and endothelial dysfunction. Neurol Sci (2009) 0.82
Deficiency of Nox2 prevents angiotensin II-induced inward remodeling in cerebral arterioles. Front Physiol (2013) 0.82
VASP phosphorylation at serine239 regulates the effects of NO on smooth muscle cell invasion and contraction of collagen. J Cell Physiol (2010) 0.82
Inhibition of apoptotic signaling and neointimal hyperplasia by tempol and nitric oxide synthase following vascular injury. J Vasc Res (2008) 0.81
Ginkgolide A-gold nanoparticles inhibit vascular smooth muscle proliferation and migration in vitro and reduce neointimal hyperplasia in a mouse model. J Surg Res (2011) 0.81
Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation. Diabetes (2010) 0.80
Angiotensin Converting Enzyme and Angiotensin II Type 1 Receptor Polymorphisms in Patients with Coronary Aneurysms. Thromb J (2003) 0.78
2-Methoxyestradiol blocks the RhoA/ROCK1 pathway in human aortic smooth muscle cells. Am J Physiol Endocrinol Metab (2015) 0.78
Angiotensin II stimulates serine phosphorylation of the adaptor protein Nck: physical association with the serine/threonine kinases Pak1 and casein kinase I. Biochem J (1999) 0.78
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease. J Diabetes Res (2016) 0.78
Nitrotyrosine promotes human aortic smooth muscle cell migration through oxidative stress and ERK1/2 activation. Biochim Biophys Acta (2008) 0.77
A single mutation in helix 8 enhances the angiotensin II type 1a receptor transport and signaling. Cell Signal (2015) 0.75
Cell-permeant peptide inhibitors of vasospasm and intimal hyperplasia. Vascular (2012) 0.75
Sildenafil Protects against Myocardial Ischemia-Reperfusion Injury Following Cardiac Arrest in a Porcine Model: Possible Role of the Renin-Angiotensin System. Int J Mol Sci (2015) 0.75
Proliferation of macrophages due to the inhibition of inducible nitric oxide synthesis by oxidized low-density lipoproteins. EXCLI J (2015) 0.75
Nitric oxide attenuates overexpression of Giα proteins in vascular smooth muscle cells from SHR: Role of ROS and ROS-mediated signaling. PLoS One (2017) 0.75
Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev (1991) 42.38
The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (1980) 40.02
Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (1988) 18.41
The L-arginine-nitric oxide pathway. N Engl J Med (1993) 14.38
The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol (1971) 10.72
Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J Pharmacol Exp Ther (1985) 9.91
Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther (1981) 6.71
Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest (1983) 6.05
Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med (1990) 5.91
Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest (1989) 5.01
Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol (1986) 4.88
K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun (1987) 3.46
Attachment of smooth muscle cells to collagen and their migration toward platelet-derived growth factor. Proc Natl Acad Sci U S A (1981) 3.31
Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res (1985) 2.28
Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest (1991) 1.96
Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease. Circ Res (1993) 1.93
Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol (1990) 1.88
Inhibition of adenylate cyclase by adenosine analogues in preparations of broken and intact human platelets. Evidence for the unidirectional control of platelet function by cyclic AMP. Biochem J (1978) 1.85
Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension (1993) 1.85
Migration of smooth muscle and endothelial cells. Critical events in restenosis. Circulation (1992) 1.77
LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase. J Pharmacol Exp Ther (1988) 1.71
Atherosclerosis or lipoprotein-induced endothelial dysfunction. Potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation (1992) 1.53
Platelet-derived growth factor suppresses and fibroblast growth factor enhances cytokine-induced production of nitric oxide by cultured smooth muscle cells. Effects on cell proliferation. Circ Res (1992) 1.42
A mechanistic and kinetic analysis of the interactions of the diastereoisomers of adenosine 3',5'-(cyclic)phosphorothioate with purified cyclic AMP-dependent protein kinase. Biochem J (1988) 1.42
Influence of the angiotensin system on endothelial and smooth muscle cell migration. Am J Pathol (1990) 1.32
Endothelium-dependent vasodilator-and nitrovasodilator-induced relaxation may be mediated through cyclic GMP formation and cyclic GMP-dependent protein phosphorylation. Trans Assoc Am Physicians (1983) 1.22
Effect of platelet factors on migration of cultured bovine aortic endothelial and smooth muscle cells. Circ Res (1989) 1.18
Pharmacology of smooth muscle cell replication. Hypertension (1992) 1.15
Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res (1991) 1.14
Cytokines and lipopolysaccharide induce nitric oxide synthase in cultured rat pulmonary artery smooth muscle. Am J Respir Cell Mol Biol (1992) 1.14
Alpha 1-adrenoreceptor blockade reduces the angiotensin II-induced vascular smooth muscle cell DNA synthesis in the rat thoracic aorta and carotid artery. Circ Res (1992) 1.03
Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension (1992) 1.03
Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol (1993) 1.02
Balloon injury and interleukin-1 beta induce nitric oxide synthase activity in rat carotid arteries. Circ Res (1992) 1.02
Vascular remodeling: mechanisms and implications. J Cardiovasc Pharmacol (1993) 1.01
Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells. J Biol Chem (1992) 1.01
Angiotensin-converting enzyme inhibitor versus angiotensin II, AT1 receptor antagonist. Effects on smooth muscle cell migration and proliferation after balloon catheter injury. Am J Pathol (1991) 0.95
Endothelial cell influences on vascular smooth muscle phenotype. Annu Rev Physiol (1986) 0.94
Culture of renal arteriolar smooth muscle cells. Mitogenic responses to angiotensin II. Circ Res (1992) 0.93
Role of angiotensin subtype 2 receptor in neointima formation after vascular injury. Hypertension (1992) 0.90
Angiotensin II receptors and functional correlates. Am J Hypertens (1992) 0.88
Independent inhibition of DNA synthesis by protein kinase C, cyclic AMP and interferon alpha/beta in rabbit aortic smooth muscle cells. Biochem Biophys Res Commun (1988) 0.87
Nitroglycerin (exogenous nitric oxide) substitutes for endothelium-derived nitric oxide in potentiating vasorelaxations and cyclic AMP elevations induced by calcitonin gene-related peptide (CGRP) in rat aorta. Neuropeptides (1994) 0.83
Quantitative methods for scoring cell migration and invasion in filter-based assays. Anal Biochem (1993) 0.83
Culture of rat mesenteric arteriolar smooth muscle cells: effects of platelet-derived growth factor, angiotensin, and nitric oxide on growth. Cell Tissue Res (1994) 0.82
Simultaneous activation of adenylyl cyclase and protein kinase C induces production of nitric oxide by vascular smooth muscle cells. Mol Pharmacol (1994) 0.81
Vasodilator-derived nitric oxide inhibits fetal calf serum- and angiotensin-II-induced growth of renal arteriolar smooth muscle cells. J Pharmacol Exp Ther (1994) 0.81
Autocrine-paracrine factors and vascular remodeling in hypertension. Curr Opin Nephrol Hypertens (1993) 0.80
Endothelium reduces DNA synthesis in isolated arteries. Am J Physiol (1991) 0.77
Angiotensin II production in different vascular beds in hypertensive subjects. J Hypertens Suppl (1991) 0.77
The acetylene-ethylene assay for n(2) fixation: laboratory and field evaluation. Plant Physiol (1968) 28.49
Connective tissue growth factor induces apoptosis in human breast cancer cell line MCF-7. J Biol Chem (1999) 6.59
Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation (1995) 4.59
Assessment of myocardial perfusion in coronary artery disease by magnetic resonance: a comparison with positron emission tomography and coronary angiography. Circulation (2001) 3.38
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation (1996) 3.28
Enhanced peroxynitrite formation is associated with vascular aging. J Exp Med (2000) 3.09
Acute heart transplant rejection due to Saint John's wort. Lancet (2000) 2.71
Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation (1994) 2.69
Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest (1990) 2.61
High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation (1997) 2.51
Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension (1986) 2.30
Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation (1998) 2.27
Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation (1996) 2.05
Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. Circulation (1990) 1.98
Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation (1991) 1.96
Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation (2000) 1.93
Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging with various contrast medium doses: first European multi-centre experience. Eur Heart J (2004) 1.76
Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation (1997) 1.67
Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest (1998) 1.62
Interstitial brain adenosine and xanthine increase during jugular venous oxygen desaturations in humans after traumatic brain injury. Crit Care Med (2001) 1.59
Endothelial dysfunction in diabetes mellitus. J Cardiovasc Pharmacol (1998) 1.58
Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain beta-amyloid production. Neuroscience (2006) 1.53
Increased adenosine in cerebrospinal fluid after severe traumatic brain injury in infants and children: association with severity of injury and excitotoxicity. Crit Care Med (2001) 1.52
Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. J Clin Invest (1996) 1.50
Fibromuscular hyperplasia: extension of the disease and therapeutic outcome. Results of the University Hospital Zurich Cooperative Study on Fibromuscular Hyperplasia. Nephron (1986) 1.47
Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. Hypertension (1990) 1.47
Predictors of long-term survival after valve replacement for chronic aortic regurgitation; is M-mode echocardiography sufficient? Eur Heart J (2001) 1.47
Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci U S A (2000) 1.47
Endothelin. Key to coronary vasospasm? Circulation (1991) 1.46
Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart (2007) 1.45
Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med (1988) 1.45
Aging, serum estradiol levels, and pregnancy differentially affect vascular reactivity of the rat uterine artery. J Soc Gynecol Investig (2000) 1.44
Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol (2000) 1.43
Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. A new mechanism of vasospasm? Circulation (1990) 1.42
Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension (1997) 1.41
Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler Thromb Vasc Biol (2001) 1.40
Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res (1999) 1.39
[Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions]. Schweiz Med Wochenschr (1997) 1.39
Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: role of Rho/ROCK and mitogen-activated protein kinase. Circ Res (2001) 1.36
Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation (2000) 1.35
Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension (1995) 1.34
Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol (2001) 1.33
The vascular endothelium as a regulator of the ocular circulation: a new concept in ophthalmology? Surv Ophthalmol (1995) 1.32
Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors. Hypertension (1998) 1.31
Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension (1987) 1.30
Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries. Am J Physiol (1990) 1.28
Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A (1998) 1.26
Compliance in hypertension: facts and concepts. J Hypertens Suppl (1985) 1.25
Exogenous and endogenous adenosine inhibits fetal calf serum-induced growth of rat cardiac fibroblasts: role of A2B receptors. Circulation (1997) 1.24
Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease? Circulation (2001) 1.23
Teaching clinical pharmacology and therapeutics: selective for fourth-year medical students. J Clin Pharmacol (1998) 1.22
Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation (1997) 1.22
Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation (1998) 1.20
Decreased expression of Kv4.2 and novel Kv4.3 K+ channel subunit mRNAs in ventricles of renovascular hypertensive rats. Circ Res (1997) 1.20
Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med (1988) 1.19
Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Vis Sci (1992) 1.19
Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade. Circulation (1999) 1.18
A(2b) receptors mediate the antimitogenic effects of adenosine in cardiac fibroblasts. Hypertension (2001) 1.18
Connective tissue growth factor. Friend or foe? Arterioscler Thromb Vasc Biol (1997) 1.17
Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension (1996) 1.16
Adenosine inhibits growth of human aortic smooth muscle cells via A2B receptors. Hypertension (1998) 1.15
Dark chocolate improves endothelial and platelet function. Heart (2006) 1.15
Importance of endothelium-derived nitric oxide in porcine coronary resistance arteries. Am J Physiol (1991) 1.15
A(2B) receptors mediate antimitogenesis in vascular smooth muscle cells. Hypertension (2000) 1.15
Different activation of the endothelial L-arginine and cyclooxygenase pathway in the human internal mammary artery and saphenous vein. Circ Res (1991) 1.14
The in situ blood perfused rat mesentery; a model for assessing modulation of adrenergic neurotransmission. Eur J Pharmacol (1980) 1.12
Simple renal cyst and hypertension: cause or coincidence? Clin Nephrol (1986) 1.11
Effects of chronic ETA-receptor blockade in angiotensin II-induced hypertension. Hypertension (1997) 1.10
Pulsatile stretch stimulates superoxide production and activates nuclear factor-kappa B in human coronary smooth muscle. Circ Res (1997) 1.09
Adenosine inhibits growth of rat aortic smooth muscle cells. Possible role of A2b receptor. Hypertension (1996) 1.09
Overexpression of connective tissue growth factor gene induces apoptosis in human aortic smooth muscle cells. Circulation (1999) 1.08
Effect of aminophylline on renal vasoconstriction produced by amphotericin B in the rat. Naunyn Schmiedebergs Arch Pharmacol (1983) 1.08
Human CD4+ CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells. Clin Exp Immunol (2014) 1.08
Local anesthetic drugs reduce endothelium-dependent relaxations of porcine ciliary arteries. Invest Ophthalmol Vis Sci (1993) 1.07
Pulsatile stretch stimulates superoxide production in human aortic endothelial cells. Circulation (1997) 1.07
17Beta-estradiol, its metabolites, and progesterone inhibit cardiac fibroblast growth. Hypertension (1998) 1.07
Modulation by angiotensin II of isoproterenol-induced cAMP production in preglomerular microvascular smooth muscle cells from normotensive and genetically hypertensive rats. J Pharmacol Exp Ther (1998) 1.05
Physician compliance with advanced electronic alerts for preventing venous thromboembolism among hospitalized medical patients. J Thromb Haemost (2009) 1.05
Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res (1992) 1.04
Impaired endothelium-dependent relaxations in hypertensive resistance arteries involve cyclooxygenase pathway. Am J Physiol (1990) 1.04
Clinically used estrogens differentially inhibit human aortic smooth muscle cell growth and mitogen-activated protein kinase activity. Arterioscler Thromb Vasc Biol (2000) 1.04
Cardiovascular protective effects of 17beta-estradiol metabolites. J Appl Physiol (1985) (2001) 1.04
Role of nitric oxide in the regulation of the mechanical properties of peripheral conduit arteries in humans. Hypertension (1997) 1.03
Academic detailing improves identification and reporting of adverse drug events. Pharm World Sci (1999) 1.03
Low density lipoprotein cholesterol and coronary microvascular dysfunction in hypercholesterolemia. J Am Coll Cardiol (2000) 1.03
Endothelin-1 in pulmonary hypertension associated with high-altitude exposure. Circulation (1995) 1.02
Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation (1998) 1.02
Endogenous cyclic AMP-adenosine pathway regulates cardiac fibroblast growth. Hypertension (2001) 1.01
Obesity is associated with tissue-specific activation of renal angiotensin-converting enzyme in vivo: evidence for a regulatory role of endothelin. Hypertension (2000) 1.01
Estradiol inhibits smooth muscle cell growth in part by activating the cAMP-adenosine pathway. Hypertension (2000) 1.01
Amphotericin-B nephrotoxicity in humans decreased by sodium supplements with coadministration of ticarcillin or intravenous saline. Klin Wochenschr (1987) 1.00
Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension (1999) 1.00
Cyclic AMP-adenosine pathway induces nitric oxide synthesis in aortic smooth muscle cells. Hypertension (1998) 1.00
Endothelium-dependent regulation of the ophthalmic microcirculation in the perfused porcine eye: role of nitric oxide and endothelins. Invest Ophthalmol Vis Sci (1993) 1.00
Effects of long-term caffeine consumption on renal function in spontaneously hypertensive heart failure prone rats. J Cardiovasc Pharmacol (1999) 1.00
Magnetic resonance-based assessment of global coronary flow and flow reserve and its relation to left ventricular functional parameters: a comparison with positron emission tomography. Circulation (2000) 1.00
Role of renal prostaglandins in sympathetically mediated renin relase in the rat. J Clin Invest (1979) 1.00
Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J Am Coll Cardiol (2001) 1.00
Circulating nitric oxide (nitrite/nitrate) levels in postmenopausal women substituted with 17 beta-estradiol and norethisterone acetate. A two-year follow-up study. Hypertension (1995) 1.00